The short answer
The National Academies' 2017 review concluded that evidence was insufficient to support or refute dronabinol as an IBS symptom treatment. It identified one small, two-day trial (36 participants) with no overall effect on gastrointestinal transit. Dronabinol is not the same as testing every cannabis product or outcome, and the review is not current enough to settle later evidence. A 2024 GI systematic review also found heterogeneous studies and broad evidence gaps; it did not establish cannabis as an IBS treatment.
What to track and ask
If discussing symptoms with a clinician, a simple diary can note bowel symptoms, meals, sleep, stress, medicines, cannabis product/route and timing. This is a discussion aid, not a diagnostic tool or reason to change treatment. Ask what established evaluation or treatment options fit your symptoms and whether cannabis could interact with medicines. See our interaction overview.
Questions readers ask
Does cannabis cure IBS?
The sources do not establish that. The National Academies review was specifically insufficient for dronabinol and described a small, short trial; it cannot answer every formulation or patient outcome.
Does "insufficient evidence" mean it cannot help anyone?
No. It means the available studies did not support a confident conclusion; it is not proof of no effect.
Sources
- National Academies: Committee conclusions (2017)
- PubMed: Systematic review of cannabis and gastrointestinal symptoms
- Wiley: Original randomized dronabinol IBS-D trial
Sources checked September 24, 2026.